Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Histiocytic sarcoma (HS) is associated with a poor prognosis owing to the presence of metastasis at the time of diagnosis in most dogs. Improved outcome has been reported in several dogs with localized HS following local therapy, however, distant metastasis occurs in 70-91% of dogs suggesting that adjuvant systemic therapy is necessary. The purpose of this retrospective study was to describe clinical characteristics and outcome in dogs with localized HS treated with aggressive local therapy plus adjuvant CCNU chemotherapy. Data from 16 dogs were evaluated. The median disease-free interval was 243 days. Two dogs had local recurrence and eight dogs developed metastatic disease with a median time to relapse of 201 days in these 10 dogs. The median survival time for all 16 dogs was 568 days. These results support the recommendation for aggressive local therapy combined with adjuvant CCNU chemotherapy in dogs with localized HS.
Skorupski
K A
KA
Department of Surgical and Radiological Sciences, University of California, Davis, CA 95616, USA. kskorups@ucdavis.edu
Rodriguez
C O
CO
Krick
E L
EL
Clifford
C A
CA
Ward
R
R
Kent
M S
MS
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D015331:Cohort Studies; D018572:Disease-Free Survival; D004283:Dog Diseases / Q000188:drug therapy* / Q000401:mortality*; D004285:Dogs; D005260:Female; D054747:Histiocytic Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000662:veterinary*; D008130:Lomustine / Q000627:therapeutic use*; D008297:Male; D009362:Neoplasm Metastasis; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D008130:Lomustine